Ophthalmic medical device firm Sight Sciences has received CE mark approval for its Visco 360 system for the treatment of patients with glaucoma.
The new viscosurgical system has been exhibited at the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in Copenhagen, Denmark.
The new viscosurgical system has been developed to provide ophthalmologists with better access to glaucoma procedure called canaloplasty.
Visco 360 system is a fully integrated, single-handed and single-use device, which is specifically used for an ab interno approach through one single clear corneal incision.
It features an access cannula, soft and flexible microcatheter with an atraumatic tip, internal infusion pump and viscoelastic reservoir, as well as wheel that controls advancement and retraction of the microcatheter through a single finger.
According to the company, glaucoma is responsible for irreversible blindness and affects around 80 million people across the globe.
Sight Sciences founder and CEO Paul Badawi said: "Receiving CE mark approval for the Visco system and presenting positive commercial experiences with the device are major milestones for our company and, more importantly, for the treatment of patients with glaucoma.
"Canaloplasty has always been safe and effective, but adoption has been limited by the surgical complexity and the steep learning curve of the ab externo approach.”
Sight Sciences is engaged in the development of technology-driven solutions to study the physiology of ophthalmic disease.